TrialSignal
Clinical trial intelligence report
Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced Liver Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT06251115-Jul 28, 2026
NCT ID
NCT06251115
Status
RECRUITING
Phase
NA
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Executive brief
Investment-Ready Snapshot
Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced Liver Cancer is a NA clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Liver Cancer. SEO and diligence focus: QY-1-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06251115
Indication
Liver Cancer
Modality
small molecule
Target
QY-1-T
Intervention
QY-1-T
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.